# 3) Modernization Medical (MOD MED) - Fielded System Improvements and Post-Fielding Requirements

**R-2A activity** of project UN7 — Understand (Op Sys Dev)  
**Program element:** 0607384BP — Chemical and Biological Defense (Operational Systems Development)  
**Component:** Defense-Wide · **Budget Activity:** 7  
**Vintage:** President's Budget PB2027  
**Canonical URL:** https://hitchintel.com/programs/0607384BP/UN7/a2  
**Parent:** https://hitchintel.com/programs/0607384BP/UN7

## Summary

This activity requests $16.0M in FY2027, 23% of project UN7, down 12% on FY2026. The R-2A exhibit describes it across FY2025–FY2027, including what the FY2027 money is planned to buy.

## What the FY2027 request buys

**FY2027 planned work.** MOD MED will continue annual cyber security updates, management of hardware and software configurations, and develop additional pre-emergency use authorization (EUA) assays for diagnostic systems post MS C; complete Log Demo, complete Critical Design Review (CDR) and Operational Testing (OT) for the NGDS 1 Tech Refresh, continue executing regulatory activities for legacy autoinjectors, and continue post-approval stability testing to extend shelf-life of Pyridostigmine Bromide Extended-Release (PB ER) tablets.

**FY2026 to FY2027 change.** Decrease in MOD MED activities from FY 2026 to FY 2027 is primarily driven by the completion of Nonclinical and Clinical Trials for the NGDS 1 Tech Refresh effort; other activities within MOD MED are relatively stable.

## Before the request year

**FY2026 plans — current year.** MOD MED will continue annual cyber security updates, management of hardware and software configurations, and develop additional pre-emergency use authorization (EUA) assays for diagnostic systems post Milestone C; complete non-clinical, clinical, and melt window studies for the NGDS 1 Tech Refresh; execute regulatory activities for legacy autoinjectors; and begin post-approval stability testing to extend shelf-life of Pyridostigmine Bromide Extended-Release (PB ER) tablets.

**FY2025 accomplishments.** Continued developmental activities for a system to maintain the Biological Warfare diagnostics capability currently provided by Next Generation Diagnostic System Increment 1 (NGDS 1). Continued annual cyber security updates, management of hardware and software configurations, and development additional assays for emerging threats. Continued support for Army Office of the Surgeon General (OTSG) - Sponsored regulatory activities for legacy autoinjectors. Continued conducting design improvements needed for Antidote Treatment Nerve Agent Autoinjector (ATNAA) to meet FDA's reliability requirements.

## Funding

| Fiscal Year | Estimate Type | Amount ($M) |
|---|---|---|
| FY2025 | Actual | 15.0 |
| FY2026 | Enacted | 18.2 |
| FY2027 | Request | 16.0 |

> Prior, current and budget year only — an R-2A activity carries no five-year plan. It sums exactly into its project in the request year and not necessarily in any other.

## Other activities in project UN7

- [1) Chemical Biological Radiological Nuclear Support to Command and Control (CSC2)](https://hitchintel.com/programs/0607384BP/UN7/a0) — FY2027 35.1
- [2) Modernization Sensors (MOD SEN)](https://hitchintel.com/programs/0607384BP/UN7/a1) — FY2027 12.7
- 4) Special Purpose Unit Rapid Capability Development and Deployment (SPU RCDD) - System Modernization — FY2027 4.0
- 5) Weapons of Mass Destruction Civil Support Teams (WMD CST) — FY2027 2.0

## Source & machine access

- **Source:** FY2027 Office of the Secretary of Defense RDT&E Budget Justification, Exhibit R-2A, PE 0607384BP project UN7 (PB PB2027). Narrative is the government's own text.
- **No marks, no contractors at this grain** — congressional marks land on the program element and R-3 performers on the project.
- **MCP:** `mcp.hitchintel.com` — `budget_get_activity`.

*HitchAI is an independent intelligence service, not affiliated with the U.S. Department of Defense. Budget figures are requests/estimates, not obligations.*